ClinicalTrials.Veeva

Menu

Rare Glycogen Storage Diseases Natural History Study

Duke University logo

Duke University

Status

Enrolling

Conditions

GSD Type 0B
GSD XII
PRKAG2
GSD XV
Danon Disease
GSD Type 0A
GSD XIII
Polyglucosan Body Myopathy Type 2
RBCK1 Deficiency
GSD VII
Polyglucosan Body Myopathy Type 1
PGBM2
Glycogen Storage Disease
GSD X
Tarui Disease

Treatments

Other: No intervention

Study type

Observational

Funder types

Other

Identifiers

NCT06795152
Pro00115144

Details and patient eligibility

About

The purpose of this study is to collect and study key medical data about several ultra-rare GSDs (Glycogen Storage Diseases) including, but not limited to, GSD types 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease.

Full description

The immediate goal of this research is to create a natural history database to collect information from individuals who have a rare GSD. A repository of clinical, laboratory, and biochemical information on individuals with a rare GSD will allow a more definitive description of the different subtypes to be developed, which will permit development of treatment strategies in the future.

Duke will be the only site where this study takes place. However, since these are rare disorders, participants who receive care at other institutions will be included. The investigators will collect retrospective data from patient charts on diagnosed individuals, as far back as necessary to capture the clinical course of their disorder. Prospective data collected from patient charts after enrollment will be captured as well. Participant's medical records will be continually reviewed for the duration of the study.

Data will be collected from medical records and will only pertain to clinically relevant information, including, but not limited to: demographic and diagnostic information, tissue biopsy results, medical and family history, review of systems, imaging studies, results of liver, muscle, and nerve function testing, and urine and blood laboratory results.

Enrollment

200 estimated patients

Sex

All

Ages

Under 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of a rare GSD, including 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome or Danon disease

    • Two variants in the gene associated with the specific GSD type (for autosomal recessive diseases)
    • One variant in the gene associated with the specific GSD type (for autosomal dominant or X-linked diseases)
    • Deficient enzyme activity in liver, muscle, skin fibroblast or other tissue
    • One variant in causative gene with evidence of disease, per a clinician
    • Histology as confirmed by a clinician
  • Able to provide informed consent for self (adults) or affected individual (minor or adults with a legally authorized representative)

  • Able to provide consent for release of medical records

  • Pregnant women with a diagnosis of a rare GSD will be included

Exclusion criteria

  • Unable to provide informed consent for participation for one's self or by legally authorized representative/legal guardian/parent

Trial design

200 participants in 1 patient group

Rare GSD (Glycogen Storage Disease)
Description:
individuals with confirmed diagnosis of rare glycogen storage disease including but not limited to, GSD types 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease
Treatment:
Other: No intervention

Trial contacts and locations

1

Loading...

Central trial contact

Rebecca Koch, PhD, RDN; Nisha Dalal, MS, CCC-SLP

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems